Jag Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$228K Buy
+907
New +$195K 0.02% 135
2026
Q1
Sell
-909
Closed -$208K 150
2025
Q4
$208K Buy
909
+3
+0.3% +$683 0.02% 131
2025
Q3
$210K Sell
906
-350
-28% -$71.3K 0.02% 130
2025
Q2
$233K Buy
1,256
+218
+21% +$40.5K 0.03% 115
2025
Q1
$217K Sell
1,038
-1,904
-65% -$370K 0.03% 120
2024
Q4
$523K Buy
2,942
+1,744
+146% +$321K 0.07% 74
2024
Q3
$236K Buy
1,198
+31
+3% +$5.79K 0.03% 115
2024
Q2
$200K Hold
1,167
0.03% 125
2024
Q1
$213K Buy
+1,167
New +$201K 0.03% 126
2023
Q4
Sell
-11,861
Closed -$1.77M 133
2023
Q3
$1.77M Buy
11,861
+150
+1% +$22K 0.21% 79
2023
Q2
$1.58M Sell
11,711
-428
-4% -$62.8K 0.18% 88
2023
Q1
$1.93M Sell
12,139
-103
-0.8% -$15.7K 0.25% 76
2022
Q4
$1.98M Sell
12,242
-851
-6% -$130K 0.29% 73
2022
Q3
$1.76M Buy
13,093
+298
+2% +$42.8K 0.25% 78
2022
Q2
$1.96M Buy
+12,795
New +$1.96M 0.24% 72

Other funds holding ABBV

Jag Capital Management's ABBV Position: Q2 2026 in Review

Jag Capital Management opened a new position in AbbVie (ABBV) in Q2 2026: 907 shares worth $228K. The stake represents 0.02% of the portfolio and ranks #135 among its holdings. This is a return to the name: Jag Capital Management previously reported a position in ABBV as recently as Q4 2025.

Jag Capital Management first reported a position in ABBV in Q2 2022 and has held it in 15 quarters since. The position peaked at $1.98M in Q4 2022. 1,919 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Jag Capital Management held 907 shares of AbbVie worth $228K as of Q2 2026.
  • AbbVie was a new Jag Capital Management position in Q2 2026.
  • AbbVie made up 0.02% of Jag Capital Management's portfolio in Q2 2026, its #135 holding.
  • Jag Capital Management first reported a position in AbbVie in Q2 2022 and has held it in 15 quarters since.
  • Jag Capital Management's AbbVie position peaked at $1.98M in Q4 2022.
  • 1,919 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Jag Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.